Objectives Penpulimab is a novel programmed death-1 (PD-1) inhibitor that has been approved in China for use in combination with chemotherapy as a first-line treatment for locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC). However. the cost-effectiveness of this treatment in China remains to be determined. In this study. https://foldlyers.shop/product-category/sub-assemblies/